Prevalence and Risk Factors of Acute Pancreatitis in Childhood Acute Leukemia
Authors:
- Kamonluk ThepuatrakulKTKamonluk Thepuatrakul
- Atchariya ChanpongACAtchariya Chanpong
- Natsaruth SongthaweeNSNatsaruth Songthawee
- Pornpun SripornsawanPSPornpun Sripornsawan
- Sirinthip KittivisuitSKSirinthip Kittivisuit
- Hansa SriphongphankulHSHansa Sriphongphankul
- Thirachit ChotsampancharoenTCThirachit Chotsampancharoen
Open Access
Abstract
Background/Objectives: Acute pancreatitis (AP) is an uncommon but serious complication in children undergoing treatment for acute leukemia. We aimed to determine the prevalence of AP in pediatric patients with acute leukemia, identify its risk factors, and evaluate their impact on treatment outcomes and overall survival. Materials and Methods: We retrospectively reviewed the medical records of children with acute leukemia who developed acute abdominal pain suggestive of AP at Songklanagarind Hospital between 2004 and 2024. Demographic data, including leukemia subtypes, treatment protocols, and clinical outcomes, were compared between the patients with and without AP. Results: Of the 618 patients with leukemia, 70 children with abdominal pain were identified, and 17 were diagnosed with AP. The prevalence of AP was 2.8%. Most children with acute leukemia and AP had T-cell subtypes (50.0%) and received high- to very-high-risk treatment protocols (76.5%). Patients with AP experienced a shorter duration of abdominal pain before diagnosis and required imaging more frequently than the non-AP patients did (100% vs. 56.6%). They required a prolonged fasting period and greater intravenous fluid volume within 48 h. The overall mortality rate (all-cause during follow-up) was significantly higher in the AP group. Using high- to very-high-risk chemotherapy protocols was a risk factor for AP, and the accumulative L-asparaginase dose of ≥55,200 IU/m2 could increase AP risk. Conclusions: AP is significantly associated with increased overall mortality in children with acute leukemia. Careful monitoring of L-asparaginase dosing may be required. Larger studies are needed to better identify the risk factors and preventive strategies.Keywords
This publication has 36 references indexed in Scilit:
- Risk factors and a prediction model of severe asparaginase-associated pancreatitis in childrenAnnals of Hematology, 2024
- Acute Pancreatitis: Diagnosis and TreatmentDrugs, 2022
- Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensityPediatric Research, 2021
- Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group studyThe Lancet Oncology, 2017
- AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemiaCancer, 2011
- Acute pancreatitisThe Lancet, 2008
- Predicting asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2006
- The treatment of children with acute lymphoblastic leukemia in ThailandMedical and Pediatric Oncology, 2002
- INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURESThe Lancet, 1988
- The staging of childhood acute lymphoblastic leukemia: Strategies of the childrens cancer study group and a three-dimensional technic of multivariate analysisMedical and Pediatric Oncology, 1986